Newsletter

February 2024

Positive one-year follow-up data from Phase 2 trial of denovoSkin™

Press release /

Switzerland, 14 February 2024 – CUTISS AG, a Swiss clinical-stage life science company focused on skin regenerative medicine and tissue engineering, has announced positive one-year follow-up data from its Phase 2 clinical trial of the lead product denovoSkin™, in adult and adolescent severe burn patients. Following the announced positive primary endpoint in Q1 2023, the one-year readout […]

Positive one-year follow-up data from Phase 2 trial of denovoSkin™ Read More »

TeleZüri features CUTISS’s denovoSkin™: Advancing Burn Treatment

Media /

Discover CUTISS’s strides in developing the personalized skin tissue therapy denovoSkin™, as seen on TeleZüri’s CheckUp. The segment shares a patient’s remarkable recovery story, demonstrates how our pioneering skin graft technology can positively impact patients’ lives, and includes insights from CEO Dr. Daniela Marino. Watch the reportage to see the significant advancements denovoSkin™ brings to

TeleZüri features CUTISS’s denovoSkin™: Advancing Burn Treatment Read More »

Contact Us

Main Office / R&D / GMP Laboratories

CUTISS AG
CUTISS HAUS
Grabenstrasse 11
8952 Schlieren, Switzerland

info@cutiss.swiss
Tel. +41 44 244 36 60

Facebook Twitter Linkedin Youtube Instagram
Media Contact

Main office / R&D / GMP Laboratories

© Cutiss AG. All rights reserved.

Data Protection & Impressum

Phone
Email
Contact
Top
Scroll to Top

Newsletter

Would you like to contact us as a journalist?

©WyssZurich

This website uses cookies to ensure you get the best experience on our website.

Accept